Company intelligence / Profile preview

Immunofusion

Charleroi, Wallonia, Belgium

Ownership: Private
Development stage: Preclinical

Overview

Immunofusion is developing a cell therapy for single-shot cure for lymphomas. The company has been selected as one of eight biotech startups across Europe with the opportunity to engage with top-tier investors and key players in the biotech industry.

Therapeutic areas: Oncology
Modalities: Cell therapyCAR-TNK-CARAntibody engineering
Industry: Biotech

Drug pipeline

1 asset

TanCAR

Preclinical

Beyond the preview

Go deeper on Immunofusion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunofusion.

Explore the full profile